In one paragraphSynthesis in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Nathan W Watson *Department of Medicine (N.W.W.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Syed Bukhari *Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD (S.B.).ORCID 0000-0002-0244-3716 Sina RashediDivision of Cardiovascular Medicine, Department of Medicine (S.R., M.P., S.Z.G., G.P., B. Bikdeli), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-0146-5611 Mariana PfefermanDivision of Cardiovascular Medicine, Department of Medicine (S.R., M.P., S.Z.G., G.P., B. Bikdeli), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-7486-4915 Francisco UjuetaDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN (F.U.).ORCID 0000-0002-5346-7996 Bassil BacareDivision of Cardiology, Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.R., M.P., B. Bacare, S.Z.G., G.P., B. Bikdeli).
Mehrdad ZarghamiDepartment of Internal Medicine, Jamaica Hospital Medical Center, Queens, NY (M.Z.).ORCID 0000-0003-0549-951X Yogendra KanthiSection of Vascular Thrombosis & Inflammation, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD (Y.K.).ORCID 0000-0002-5660-5194 Eric A SecemskyRichard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (E.A.S.).ORCID 0000-0003-3861-3163 Jean M ConnorsDivision of Hematology (J.M.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0001-6445-582X Geoffrey D BarnesDivision of Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor (G.D.B.).ORCID 0000-0002-6532-8440 Sacha UljonDepartment of Pathology, Massachusetts General Hospital, Mass General Brigham, Boston (S.U.).ORCID 0000-0001-5190-6652 Samuel Z GoldhaberDivision of Cardiovascular Medicine, Department of Medicine (S.R., M.P., S.Z.G., G.P., B. Bikdeli), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-6450-0448 Jeffrey I WeitzMcMaster University, Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, ON, Canada (J.I.W.).ORCID 0000-0002-1092-7550 Karen H CostenbaderDivision of Rheumatology, Inflammation and Immunity, Department of Medicine (K.H.C.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-8972-9388 Harlan M KrumholzYNHH/Yale Center for Outcomes Research and Evaluation (CORE), New Haven, CT (H.M.K., B. Bikdeli).ORCID 0000-0003-2046-127X Gregory PiazzaDivision of Cardiovascular Medicine, Department of Medicine (S.R., M.P., S.Z.G., G.P., B. Bikdeli), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-1722-2983 Mary CushmanDivision of Hematology and Oncology, Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT (M.C.).ORCID 0000-0002-7871-6143 Christopher D AndersonDepartment of Neurology (C.D.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-0053-2002 Mitchell S V ElkindDepartment of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, NY (M.S.V.E.).ORCID 0000-0003-2562-1156 Behnood BikdeliDivision of Cardiovascular Medicine, Department of Medicine (S.R., M.P., S.Z.G., G.P., B. Bikdeli), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-1428-879X Funding
Human Translational Studies of Vascular Thrombosis and InflammationZIAHL006262 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI KANTHI, YOGENDRA · 2021 to 2025
$4.7MIntramural NIH HHS ZIA HL006262
6 · The paper itselfAbstract
backgroundAntiphospholipid antibodies (aPL) are associated with an increased risk of thrombosis. However, individual studies have reported conflicting findings regarding the prevalence of aPL in patients with ischemic stroke and their association with first or recurrent events.
methodsSystematic searches of PubMed and Embase through May 13, 2025 were conducted to identify case-control, cohort, or cross-sectional studies investigating 3 questions related to aPL seropositivity (defined as positivity for either immunoglobulin G/immunoglobulin M anticardiolipin antibody, immunoglobulin G/immunoglobulin M anti-β2 glycoprotein I antibody, or a lupus anticoagulant): (1) the prevalence of aPL seropositivity among individuals with ischemic stroke; (2) the association between aPL seropositivity and the risk of first ischemic stroke; and (3) the association between aPL seropositivity and the risk of recurrent ischemic stroke. Random-effects models with inverse weighting were used to calculate pooled prevalences and odds ratios (OR) with 95% CIs. Risk of bias was assessed using the ROBINS-I tool.
resultsA total of 52 studies were included (40 case-control, 12 cohort). The pooled prevalence of seropositivity for any aPL among patients with ischemic stroke (51 studies, 9438 patients) was 19.1% (95% CI, 15.4%-23.0%;
conclusionsSeropositivity for any aPL was present in nearly 1-in-5 patients with ischemic stroke and was associated with increased odds of ischemic stroke at presentation.
Indexed as
Antibodies, AntiphospholipidBrain IschemiaIschemic StrokeAntibodies, AnticardiolipinClinical RelevanceHumansAntibodies, AnticardiolipinAntibodies, Antiphospholipidantibodies, antiphospholipidantiphospholipid syndromeischemic strokeprevalencethrombosis
Identifiers
PMID42663055
PMCPMC13528693
What Socratic holds
Textmetadata
Read underepoch 390